{"pub_date": "2016-09-22T04:00:00+0000", "subsection_name": null, "lead_paragraph": "Heather Bresch, the chief executive of Mylan, told a skeptical House panel that her company had struck a balance between price and access.", "print_page": "3", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "THOMAS", "firstname": "Katie", "role": "reported"}], "original": "By KATIE THOMAS"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 400, "url": "images/2016/09/22/business/22MYLAN/22MYLAN-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/09/22/business/22MYLAN/22MYLAN-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "Mylan Chief\u2019s Answers on EpiPen Frustrate House Panel", "main": "Mylan\u2019s Chief Is Chastised by Lawmakers Questioning EpiPen Pricing"}, "source": "The New York Times", "blog": [], "word_count": "1004", "web_url": "http://www.nytimes.com/2016/09/22/business/mylan-chief-to-insist-epipen-is-priced-fairly-at-house-hearing.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "Heather Bresch, the chief executive of Mylan, told a skeptical House panel that her company had struck a balance between price and access....", "_id": "57e2bab295d0e021d7987897", "abstract": "Mylan chief executive Heather Bresch is interrogated by House Committee on Oversight and Government Reform over huge prices increases on allergy treatment EpiPen; panel expresses frustration as she defends firm's practices.", "keywords": [{"rank": "1", "name": "organizations", "value": "Mylan Inc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Epinephrine (Drug)", "is_major": "N"}, {"rank": "3", "name": "subject", "value": "Medical Devices", "is_major": "N"}, {"rank": "4", "name": "persons", "value": "Bresch, Heather", "is_major": "Y"}, {"rank": "5", "name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N"}, {"rank": "6", "name": "organizations", "value": "House Committee on Oversight and Government Reform", "is_major": "N"}, {"rank": "7", "name": "subject", "value": "Allergies", "is_major": "Y"}, {"rank": "9", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}]}